The US Food and Drug Administration (FDA) has approved Ozempic® (semaglutide; Novo Nordisk) injection to treat adults with type 2 diabetes.1

The once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist showed “clinically meaningful and statistically significant” HbA1c reductions in study participants vs placebo, sitagliptin, and exenatide extended release. The phase 3a clinical trial program (SUSTAIN™; NCT02054897, NCT01930188, NCT01885208, NCT02128932, NCT02305381, and NCT01720446) involved more than 8000 adults with type 2 diabetes and included an outcomes trial examining cardiovascular safety.2

“The approval of semaglutide offers healthcare professionals an important new treatment option to help adults with type 2 diabetes meet their A1c goals,” said Helena Rodbard, MD, FACP, MACE, medical director of Endocrine and Metabolic Consultants in Rockville, MD, in a press release.1

Used in conjunction with diet and exercise, Ozempic is administered once weekly. It is expected to launch in early 2018 and will be available in 0.5-mg and 1-mg doses delivered via prefilled pen.

Continue Reading

Related Articles

Possible Ozempic side effects include thyroid tumors, pancreatitis, hypoglycemia, or kidney failure. Ozempic is not intended for use in people with type 1 diabetes.


  1. Novo Nordisk receives FDA approval of Ozempic® (semaglutide) injection for the treatment of adults with type 2 diabetes [news release]. Plainsboro, NJ: Novo Nordisk Inc. Published December 5, 2017. Accessed December 5, 2017.
  2. OZEMPIC® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2017.

This article originally appeared on Endocrinology Advisor